Fusogenic lipid nanoparticles for target cell-specific production of a therapeutic protein
AssigneeOisin Biotechnologies, Inc.
InventorsMatthew Rein Scholz, John David Lewis, Gary Charles Hudson
Life of this patent
Estimating the term…
Loading patent…
AssigneeOisin Biotechnologies, Inc.
InventorsMatthew Rein Scholz, John David Lewis, Gary Charles Hudson
Estimating the term…
Provided nucleic acid-based expression construct for the target cell-specific production of a therapeutic protein, such as a pro-apoptotic protein, within a target cell, including a target cell that is associated with aging, disease, or other condition, in particular a target cell that is a senescent cell or a cancer cell. Also provided are formulations and systems, including fusogenic lipid nanoparticle (LNP) formulations and systems, for the delivery of nucleic acid-based expression constructs as well as methods for making and using such nucleic acid-based expression constructs, formulations, and systems for reducing, preventing, and/or eliminating the growth and/or survival of a cell, such as a senescent cell and/or a cancer cell, which is associated with aging, disease, or other condition as well as methods for the treatment of aging, disease, or other conditions by the in vivo administration of a formulation, such as a fusogenic LPN formulation, comprising an expression construct for the target cell-specific production of a therapeutic protein, such as a pro-apoptotic protein, in a target cell that is associated with aging, disease, or other condition, in particular a target cell that is a senescent cell or a cancer cell.
A lipid-based nanoparticle (LNP) formulation for targeted production of a therapeutic protein within Hall target cells, the LNP formulation comprising:
A method of treating a condition in a subject in need thereof, the method comprising administering to the subject one or more lipid-based nanoparticle (LNP) formulations, the one or more LNP formulations comprising:
Dependencies are inferred from the claim text.